NRX Pharmaceuticals Inc’s recently made public that its Chairman and Chief Scientist Javitt Jonathan C acquired Company’s shares for reported $46800.0 on Dec 17 ’24. In the deal valued at $1.17 per share,40,000 shares were bought. As a result of this transaction, Javitt Jonathan C now holds 84,634 shares worth roughly $0.24 million.
Price Performance Review of NRXP
On Monday, NRX Pharmaceuticals Inc [NASDAQ:NRXP] saw its stock fall -11.49% to $2.85. Over the last five days, the stock has lost -28.93%. NRX Pharmaceuticals Inc shares have risen nearly 29.55% since the year began. Nevertheless, the stocks have fallen -35.08% over the past one year. While a 52-week high of $7.33 was reached on 01/13/25, a 52-week low of $1.10 was recorded on 01/02/25. SMA at 50 days reached $2.14, while 200 days put it at $2.32.
Levels Of Support And Resistance For NRXP Stock
The 24-hour chart illustrates a support level at 2.55, which if violated will result in even more drops to 2.25. On the upside, there is a resistance level at 3.40. A further resistance level may holdings at 3.95. The Relative Strength Index (RSI) on the 14-day chart is 47.82, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.97, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.18%. Stochastics %K at 14.74% indicates the stock is a buying.
How much short interest is there in NRX Pharmaceuticals Inc?
A steep rise in short interest was recorded in NRX Pharmaceuticals Inc stocks on 2024-10-31, growing by 0.15 million shares to a total of 0.68 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 0.53 million shares. There was a rise of 22.06%, which implies that there is a positive sentiment for the stock.
